Aticaprant: (a κ-opioid receptor antagonist) for major depressive disorder

Research output: Contribution to journalReview articlepeer-review


INTRODUCTION: Major depression is a common, disabling mental health condition associated with the highest disease burden for any neuropsychiatric disorder worldwide, according to the WHO. Due to the imperfect efficacy and tolerability profiles of existing treatments, investigational compounds in novel treatment classes are needed. Opioid-receptor antagonists are a potential new class of treatments currently under investigation.

AREAS COVERED: Major depressive disorder is first overviewed. Existing treatments, both their mechanisms of action and their place within the antidepressant space, are discussed herein. Then, the profile of Aticaprant and the wider context of kappa-opioid antagonism for depression are discussed in focus.

EXPERT OPINION: Early evidence indicates that Aticaprant may possess desirable pharmacodynamic and pharmacokinetic properties. A lack of convincing efficacy data at the time of writing precludes any definitive statement on its potential as an antidepressant.

Original languageEnglish
Pages (from-to)1-12
Number of pages12
JournalExpert Opinion on Emerging Drugs
Publication statusE-pub ahead of print - 8 May 2024


Dive into the research topics of 'Aticaprant: (a κ-opioid receptor antagonist) for major depressive disorder'. Together they form a unique fingerprint.

Cite this